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Summary
Osteoarthritis is increasingly recognized as a complex illness in which interrelationships between the different tissues of the joint are
important. We are still some way from a complete understanding of the pathophysiologic and temporal relationships between bone, synovial
tissue and cartilage. Recent evidence points to a significant role for cytokines and growth factors in osteoarthritis that leads to a
preponderance of catabolic processes in the joint.
In-vitro culture of human cartilage has been used as a model to measure the effects of drugs used in the treatment of osteoarthritis on
anabolic and catabolic processes. On this basis, the nonsteroidal antiinflammatory drugs can be categorized into one of three classes
depending on whether they are inhibitory (e.g., indomethacin and naproxen), neutral (e.g., diclofenac, aspirin and piroxicam) or stimulatory
(e.g., aceclofenac, tenidap and tolmetin) of glycosaminoglycan synthesis in chondrocytes. The marked differences between these
nonsteroidal antiinflammatory drugs suggest that a mechanism other than cyclooxygenase inhibition is involved in their effects on
glycosaminoglycan synthesis. Inhibition of IL-1 b and the stimulation of growth factors are suggested as possible mechanisms.
Although the significance of these properties of nonsteroidal antiinflammatory drugs awaits confirmation in in-vivo and clinical situations,
they do provide the clinician with a new parameter with which to choose therapy in osteoarthritis.
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venue for opinion leaders in the field of rheumatology to air
their views on the current clinical and basic research
aspects of osteoarthritis (OA). The workshop provided a
forum for presentations about the individual tissues
involved in OA and more general discussions about the
influence of tissue cross-talking on the progression of
OA and on the role of nonsteroidal antiinflammatory drugs
(NSAIDs). The aim of this summary is to recapitulate
some of the points that were raised in the round table
discussions.We live in a global world
OA is a common disease characterized by localized
damage to the synovial joint. The widely held dogma in
early investigations into the mechanisms involved in OA
was that if more mechanical load were put on a joint, the
more the cartilage would be eroded. The precise cause of
OA remains elusive. It is realized, however, that a complex
interplay exists between all joint tissues and that OA is not
solely related to the erosion of cartilage but that pathologi-
cal changes to synovial and subchondral bone also occur.
Indeed, it is associated with a sequence of clinical and
pathological changes that occur in response to mechanical
and biochemical stimuli and result in destruction of the
articular cartilage, new bone formation at the joint margins
and eventual failure of the joint.Tissues, catabolism and anabolism
The cytokines are considered an interesting link in OA
since they are produced by many of the cells present in the374OA joint. They are responsible, in part, for the changes
seen in cartilage damage, the synovial membrane,
subchondral bone and osteophyte formation.
In the normal joint, a delicate balance of degradation
and repair processes maintains the entirety of the
cartilage matrix. In OA, this equilibrium is disrupted and
the catabolic processes prevail leading to the loss of joint
integrity. Changes in the metabolic activity, or perhaps in
the phenotype, of chondrocytes are thought to play a role
in this process. Even in severe OA, chondrocytes retain
their ability to synthesize new glycosaminoglycans
(GAGs), although this may be true of only a fraction of
the cells. Local release of catabolic cytokines, particularly
interleukin-1 beta (IL-1b ), tumor necrosis factor–alpha
(TNF-a ) and IL-6, in response to tissue damage and
inflammation can inhibit GAG synthesis and levels of
these cytokines are known to be elevated in OA. The
growth factors, transforming growth factor-beta (TGF- b )
and insulin-like growth factor (IGF)-1 serve to inhibit the
catabolic effects of these cytokines. Thus, the imbalance
between the growth factors and the cytokines represents
an important feature in the failure of the repair process. It
is not known, however, at what stage in the repair pro-
cess the damage becomes irreversible. Synovial inflam-
mation is also a feature of OA. Evidence suggests
that the synovial cells themselves contribute to the
degradation of cartilage.
Whilst articular cartilage is being lost, changes are also
occurring in the bone. Bone plays an important role in the
remodeling at the osteochondral junction and this affects
the joint shape and size. Radiological studies used in the
diagnosis of OA of the knee indicate that the subchondral
bone trabeculae become thickened, the joint space is
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seen at the joint margins. These osteophytes, which con-
tribute to the limitation of joint movement, are formed by
proliferation of cartilaginous tissue followed by endo-
chondral ossification; it has been suggested that TGF-b
may be involved in this process. Pain is thought to be
the result of synovial inflammation. However, severe pain
may also result from engorgement of bone, subchondral
ischaemia and also many other factors.Cross-talk and progression
The concept of movement of growth factors and
cytokines from bone to cartilage was brought into discus-
sion. Pathological studies by Leon Sokoloff have demon-
strated the presence of clefts or channels in the tidemark
that appear early in OA. If these are a common feature,
they set up a situation for cross-talk between bone and
cartilage. It has further been indicated that subchondral
bone in different parts of the joint, with and without OA,
produces cytokines which cause different types of reaction
on the cartilage. Thus, it is possible that bone is driving
cartilage metabolism. Bone morphologic protein has been
shown to have an anabolic effect on chondrocytes and may
promote cartilage matrix formation. This implies that signals
causing differentiation may be coming from the bone.
Using X-ray technology it is possible to show that, in
early OA, sclerosis may have overtaken the joint per se but
that changes in subchondral bone are patchy. Osteophytes
tend to form where there is vascular invasion at the outer
margins of the joint, which is also a region from where
cartilage is lost. This further suggests the role of bone
factors is driving other metabolic processes.
Multiple tissue types contribute to the development of
OA. Once the actual OA process begins, it usually
progresses to result in serious joint damage and the
‘full-blown’ clinical situation. However, it is important to
define what is meant by progression. At present, the
definitions are somewhat unclear. Progression may mean
that patients require alternative pharmacotherapy; it may
indicate that there is greater cartilage loss; it may suggest
that there is a clinical progression of pain and disability; or
it may relate to a radiographic change in joint structure.
Until there is a recognized definition of progression, clinical
outcome is probably one of the most important markers.
Clinical studies have shown some continuity between
both bone and cartilage changes as OA progresses and
experimental data suggests that there is cross-talk
between these tissues. If the bone’s response to injury and
also if associations with bone proteins could be elucidated,
it may be possible to identify factors associated with OA
progression.Models as vehicles to study OA
Basic science proceeds at an exponential rate of
discovery and new mediators and pathways that may be
relevant to OA are continually being discovered. In-vitro
methods to investigate these parameters, and the
beneficial (or otherwise) effects of particular drugs, may
provide a swift method by which to assess the processes
involved in OA and its treatment. However, are these types
of in-vitro studies always relevant for the in-vivo situation?
A number of animal models of OA have been developed
and these can provide some useful information aboutjoint mechanics and the destructive processes involved.
However, there are still doubts about their relevancy to a
disease process that takes years to develop in humans.
Whatever the animal, and whatever the method for eliciting
a process that is similar to human OA, all such studies
must be equivalent to studies in humans in terms of
predetermined outcome measures and statistical viability.
Studies using human cartilage cultured in vitro from the
cartilage of patients taking NSAIDs have shown that some
of these drugs (e.g., indomethacin, diclofenac and
naproxen) have a deleterious effect, via inhibition of GAG
synthesis, whilst others (e.g. aceclofenac, tenidap and
tolmetin) stimulate GAG synthesis. It is not clear, however,
whether these results translate to the same process in vivo.
There is a series of problems associated with extrapolation
from in-vitro to in-vivo situations.
Unfortunately, procedures for following the rate of
change, non-invasively, in human joints with OA, in general
remain unsatisfactory. There may be plasma or synovial
fluid markers, such as keratan sulphate or hyaluronan, that
can be used to follow changes, but these are not neces-
sarily of real value. Moreover, although some drugs may
have disease modifying properties, the capacity for deter-
mining the extent of the changes they may produce in the
patient is far from complete.The role of NSAIDs in OA treatment
The treatments currently available for OA afford only
palliative care. The prescription of simple analgesics
(acetaminophen) to reduce pain generally precedes
treatment with NSAIDs. If these simple analgesics prove
ineffective, NSAIDs may be prescribed either alone or in
combination with an analgesic. Although NSAIDs are
clinically important for relieving the symptoms of pain and
inflammation, their mechanisms of action are not yet fully
understood.
The NSAIDs have been categorized with respect to their
actions in vitro on cartilage:
• Those which can stimulate GAG synthesis (such as
aceclofenac, tenidap and tolmetin)
• Those without a significant effect (such as diclofenac,
aspirin and piroxicam)
• Those which significantly inhibit GAG synthesis (such as
naproxen, ibuprofen and indomethacin)
Although NSAIDs are efficacious for acute and chronic
pain, their role in the treatment of OA is not completely
resolved and there is still much to be learned. It is clear that
there are differences between NSAIDs. Although all
NSAIDs inhibit the production of PGE2, some also inhibit
matrix component synthesis. There may be other mecha-
nisms, in addition, which explain the different properties of
different NSAIDs. Moreover, although there is data com-
paring NSAIDs to one another, there is very little data
that compares NSAIDs to simple analgesics. Each
NSAID therefore needs to be evaluated separately for its
effectiveness in treatment.The ideal NSAID
Although imperfect, NSAIDs are the most widely used
drug therapy in OA. There are other possibilities on the
horizon, but for now, the therapeutic challenge is to select
the ideal NSAID. From the cartilage perspective the ideal
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decrease chondroresorption and also decrease the
synthesis of catabolic cytokines.The future
It is clear that considerable progress has been made
towards greater understanding of the underlying mech-
anisms involved in OA. There are, nevertheless, several
questions that remain unanswered. Progression and tissue
cross-talking in OA were the main themes of the workshop,
but one aspect of this complex interaction was perhaps
overlooked. Progression was alluded to as being the
advancement of a series of pathological features resulting
from aberrant biochemistry in the joint. However, what
causes the joint to progress from dormancy to an active site
of such processes and whether there is any way in
which this can be accurately evaluated need to be further
examined.
The role of NSAIDs was brought into question and
alternative therapies were discussed. However, until such
time as alternative therapies can be proven to be effective
in vitro, in animal models in vivo and in clinical trials,
NSAIDs look set to remain one of the mainstays of treat-
ment for OA and, perhaps most importantly, they are
currently the patients’ preferred choice. Certainly, if in the
future, NSAIDs that demonstrate the same anabolic effects
on cartilage in vivo as they do in vitro could represent a
significant therapeutic advantage. Well designed, follow-up
studies of patients taking these types of drugs will provide
some of the answers. For the immediate future, whether
prescribed alone or in combination with other analgesics or
gastroprotective drugs the treatment of OA with NSAIDs is
fairly secure.Conclusions
OA is a common disorder characterized by damage to
the structures within synovial joints. Damage can occur to
bone, synovium and cartilage and the inter-relationships
between these tissues is complex. The exact sequence of
pathophysiological events in OA remains unclear; the tem-
poral relationship between bone damage, chronic inflam-
mation of synovial tissue and cartilage erosion is unknown.In OA, the balance between anabolic and catabolic
processes is disrupted and catabolic processes predomi-
nate; cytokines and growth factors respectively are
believed to be involved in the imbalance in catabolic and
anabolic pathways.
The progressive nature of OA is clinically, radiologically,
and histologically evident although a clear marker of the
disease does not exist. In the absence of a definitive
marker for progression, clinical outcome is regarded as the
most important indicator.
A variety of measures of OA evolution and progression
have been developed. Animal models have pointed to
potential pathophysiological mechanisms, although the
application of the results of these studies to the clinical
situation remains controversial. New data, using cultured
human cartilage in vitro or ex vivo, may represent a
promising approach while results from in vivo studies are
awaited.
On the basis of in-vitro studies, NSAIDs have been
classified into three groups according to whether they are
inhibitory (e.g., indomethacin and naproxen), neutral (e.g.,
diclofenac, aspirin and piroxicam) or stimulatory (e.g.,
aceclofenac, tenidap and tolmetin) of glycosaminoglycan
synthesis in chondrocytes. There are clear differences
between NSAIDs in these studies which may be related to
their differential effects on cytokines and/or the chondrocyte
metabolic processes which they control. In this sense, the
inhibition of IL-1b and the stimulation of growth factors have
been suggested as possible explanations of the differential
activity on cartilage of aceclofenac, a well-investigated
NSAID in this field, with promising results.
It is important to evaluate the effects of the drugs
selected for treating OA on the pathophysiological pro-
cesses that occur in this disease: bone changes, synovial
inflammation and particularly cartilage destruction. In the
future, new techniques will help to clarify the evolution of
the disease, as well as the positive, negative or neutral
effects drugs may have on OA progression. In addition to
the usual concern for efficacy and safety, practitioners
should bear in mind their effect on the tissues involved in
the disease.
OA is an active process with the potential to repair.
Therefore, treatments that may stimulate these potential
repair mechanisms may present an advance over those
which do not.
